ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2023
Distinct community structures of the fungal microbiome and respiratory health in adults with cystic fibrosis.
Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Crosstalk between the microbiome and the mucosal immunoglobulin A system in the lung, in health and disease.Frontiers in cellular and infection microbiology · 2026Review
- The airway mycobiome in chronic respiratory diseases: current advances and future frontiers.Journal of translational medicine · 2025Review
- Condition-dependent effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) onMicrobiology spectrum · 2025Article
- Fungal biofilms in human health and disease.Nature reviews. Microbiology · 2025Review
- Recent developments inMicrobiology and molecular biology reviews : MMBR · 2025Review
- Article
- MycoKeys · 2025Article
- Metagenomics Applied to the Respiratory Mycobiome in Cystic Fibrosis.Mycopathologia · 2024Review
- Infection and the microbiome in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Positioning the preventive potential of microbiome treatments for cystic fibrosis in the context of current therapies.Cell reports. Medicine · 2024Review
- The gut-lung axis in the CFTR modulator era.Frontiers in cellular and infection microbiology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe respiratory tract fungal microbiome in cystic fibrosis (CF) has been understudied despite increasing recognition of fungal pathogens in CF lung disease. We sought to better understand the fungal communities in adults with CF, and to define relationships between fungal profiles and clinical characteristics.
methodsWe enrolled 66 adults with CF and collected expectorated sputum, spirometry, Cystic Fibrosis Questionnaire-revised, and clinical data. Fungi were molecularly profiled by sequencing of the internal transcribed spacer (ITS) region. Total fungal abundance was measured by quantitative PCR. Relative abundance and qPCR-corrected abundances were determined. Selective fungus culture identified cultivable fungi. Alpha diversity and beta diversity were measured and relationships with clinical parameters were interrogated.
resultsMedian age was 29 years and median FEV
conclusionThe respiratory tract fungal microbiome in adults with CF is associated with lung function, pulmonary exacerbation status, macrolide use, and CFTR modulator use. Future work to better understand fungal diversity in the CF airway and its impact on lung health is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.